The global prevalence of fusidic acid resistance in clinical isolates of Staphylococcus aureus: a systematic review and meta-analysis.
Fusidic acid
MRSA
Meta-analysis
Staphylococcus aureus
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
01 05 2021
01 05 2021
Historique:
received:
21
01
2021
accepted:
23
04
2021
entrez:
2
5
2021
pubmed:
3
5
2021
medline:
17
12
2021
Statut:
epublish
Résumé
Staphylococcus aureus (S. aureus) is one of the most common pathogens causing nosocomial and community-acquired infections with high morbidity and mortality rates. Fusidic acid has been increasingly used for the treatment of infections due to methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA). The present study aimed to determine the precise prevalence of fusidic acid resistant MRSA (FRMRSA), fusidic acid resistant MSSA (FRMSSA), and total fusidic acid resistant S. aureus (FRSA) on a global scale. Several international databases including Medline, Embase, and the Web of Sciences were searched (2000-2020) to discern studies addressing the prevalence of FRSA, FRMRSA, and FRMSSA. STATA (version14) software was used to interpret the data. Of the 1446 records identified from the databases, 215 studies fulfilled the eligibility criteria for the detection of FRSA (208 studies), FRMRSA (143 studies), and FRMSSA (71 studies). The analyses manifested that the global prevalence of FRSA, FRMRSA, and FRMSSA was 0.5%, 2.6% and 6.7%, respectively. This meta-analysis describes an increasing incidence of FRSA, FRMSSA, and FRMRSA. These results indicate the need for prudent prescription of fusidic acid to stop or diminish the incidence of fusidic acid resistance as well as the development of strategies for monitoring the efficacy of fusidic acid use.
Sections du résumé
BACKGROUND AND AIM
Staphylococcus aureus (S. aureus) is one of the most common pathogens causing nosocomial and community-acquired infections with high morbidity and mortality rates. Fusidic acid has been increasingly used for the treatment of infections due to methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA). The present study aimed to determine the precise prevalence of fusidic acid resistant MRSA (FRMRSA), fusidic acid resistant MSSA (FRMSSA), and total fusidic acid resistant S. aureus (FRSA) on a global scale.
METHODS
Several international databases including Medline, Embase, and the Web of Sciences were searched (2000-2020) to discern studies addressing the prevalence of FRSA, FRMRSA, and FRMSSA. STATA (version14) software was used to interpret the data.
RESULTS
Of the 1446 records identified from the databases, 215 studies fulfilled the eligibility criteria for the detection of FRSA (208 studies), FRMRSA (143 studies), and FRMSSA (71 studies). The analyses manifested that the global prevalence of FRSA, FRMRSA, and FRMSSA was 0.5%, 2.6% and 6.7%, respectively.
CONCLUSION
This meta-analysis describes an increasing incidence of FRSA, FRMSSA, and FRMRSA. These results indicate the need for prudent prescription of fusidic acid to stop or diminish the incidence of fusidic acid resistance as well as the development of strategies for monitoring the efficacy of fusidic acid use.
Identifiants
pubmed: 33933162
doi: 10.1186/s13756-021-00943-6
pii: 10.1186/s13756-021-00943-6
pmc: PMC8088720
doi:
Substances chimiques
Anti-Bacterial Agents
0
Fusidic Acid
59XE10C19C
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
75Références
Scand J Infect Dis. 2009;41(3):171-81
pubmed: 19173129
J Antimicrob Chemother. 2018 Apr 1;73(4):856-861
pubmed: 29253168
Med Princ Pract. 2006;15(1):39-45
pubmed: 16340226
BMJ. 2002 Jun 8;324(7350):1394
pubmed: 12053927
Br J Dermatol. 2008 Dec;159(6):1290-9
pubmed: 18795934
J Natl Cancer Inst. 1959 Apr;22(4):719-48
pubmed: 13655060
J Laryngol Otol. 2002 Sep;116(9):686-9
pubmed: 12437801
Pathology. 2019 Apr;51(3):308-312
pubmed: 30819539
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Int J Antimicrob Agents. 2015 Dec;46(6):622-30
pubmed: 26453147
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Artif Cells Nanomed Biotechnol. 2016 Sep;44(6):1464-8
pubmed: 25950954
Scand J Infect Dis. 2014 Dec;46(12):832-7
pubmed: 25229166
Arch Dis Child. 2004 Jan;89(1):74-7
pubmed: 14709515
Infect Genet Evol. 2017 Sep;53:189-194
pubmed: 28600216
Wien Klin Wochenschr. 2012 Oct;124(19-20):709-15
pubmed: 23053569
Antimicrob Agents Chemother. 2007 May;51(5):1737-40
pubmed: 17325218
Br J Gen Pract. 2010 Dec;60(581):902-6
pubmed: 21144200
Med Princ Pract. 2008;17(4):308-14
pubmed: 18523399
Infect Drug Resist. 2019 Sep 03;12:2739-2746
pubmed: 31564924
J Invest Dermatol. 2008 Nov;128(11):2655-2664
pubmed: 18596827
Rev Soc Bras Med Trop. 2018 Sep-Oct;51(5):603-609
pubmed: 30304265
J Chemother. 2005 Dec;17(6):607-13
pubmed: 16433190
Int J Microbiol. 2012;2012:391251
pubmed: 22888356
Ann Dermatol. 2015 Oct;27(5):551-6
pubmed: 26512169
Int J Antimicrob Agents. 2000 Jan;13(3):209-13
pubmed: 10724026
BMC Infect Dis. 2019 Oct 28;19(1):899
pubmed: 31660878
Wiad Lek. 2019;72(2):154-158
pubmed: 30903764
Iran J Microbiol. 2013 Mar;5(1):56-62
pubmed: 23467268
Int J Antimicrob Agents. 2002 Mar;19(3):241-3
pubmed: 11932149
PLoS One. 2017 Jun 22;12(6):e0179563
pubmed: 28640870
Antimicrob Agents Chemother. 2013 Sep;57(9):4535-6
pubmed: 23774441
Oncotarget. 2017 Jul 22;8(35):58086-58097
pubmed: 28938539
J Infect Public Health. 2013 Jun;6(3):196-201
pubmed: 23668464
Antimicrob Agents Chemother. 2010 Sep;54(9):3614-7
pubmed: 20566766
Microb Drug Resist. 2017 Jan;23(1):8-17
pubmed: 27228193
Sci Rep. 2019 Dec 6;9(1):18527
pubmed: 31811246
J Antimicrob Chemother. 2008 Mar;61(3):586-8
pubmed: 18222949
Int J Dermatol. 2016 Apr;55(4):e191-7
pubmed: 26892888
Euro Surveill. 2005 May;10(5):78-9
pubmed: 16077207
J Clin Microbiol. 2010 Mar;48(3):972-6
pubmed: 20053856
J Glob Antimicrob Resist. 2013 Dec;1(4):189-193
pubmed: 27873611
Pak J Pharm Sci. 2019 May;32(3 (Supplementary)):1219-1223
pubmed: 31303594
PLoS One. 2009;4(1):e4308
pubmed: 19180198
Pathol Biol (Paris). 2001 Feb;49(1):33-40
pubmed: 11265221
Antimicrob Agents Chemother. 2016 May 23;60(6):3827-31
pubmed: 27021326
Med J Malaysia. 2003 Jun;58(2):255-61
pubmed: 14569746
Clin Microbiol Infect. 2004 May;10(5):448-51
pubmed: 15113324
BMC Microbiol. 2015 Oct 13;15:210
pubmed: 26463589
J Infect Public Health. 2015 Jan-Feb;8(1):90-7
pubmed: 25002017
Scand J Infect Dis. 2002;34(10):729-34
pubmed: 12477322
J Antimicrob Chemother. 2008 Oct;62(4):766-8
pubmed: 18567573
Pol Merkur Lekarski. 2000 Nov;9(53):746-50
pubmed: 11204320
J Glob Antimicrob Resist. 2020 Mar;20:238-247
pubmed: 31442624
Med Princ Pract. 2017;26(5):485-490
pubmed: 28977793
An Bras Dermatol. 2016 Sep-Oct;91(5):604-610
pubmed: 27828633
J Epidemiol Glob Health. 2013 Sep;3(3):165-73
pubmed: 23932059
Emerg Microbes Infect. 2016 Dec 21;5(12):e127
pubmed: 27999423
Paediatr Int Child Health. 2012 Aug;32(3):140-6
pubmed: 22824661
PLoS One. 2016 May 26;11(5):e0156052
pubmed: 27227897
J Antimicrob Chemother. 2004 Aug;54(2):441-6
pubmed: 15269197
Asian Pac J Trop Med. 2017 Nov;10(11):1059-1064
pubmed: 29203102
Ann Dermatol Venereol. 2008 Jan;135(1):13-9
pubmed: 18342068
Int J Antimicrob Agents. 2001 Nov;18(5):445-7
pubmed: 11711260
BMJ Open. 2018 Apr 20;8(4):e020391
pubmed: 29678979
PLoS One. 2014 Jul 31;9(7):e103715
pubmed: 25078407
J Clin Microbiol. 2017 Aug;55(8):2529-2537
pubmed: 28592549
Arch Dermatol. 2002 Jul;138(7):939-41
pubmed: 12071821
Int J Dermatol. 2013 Jul;52(7):876-81
pubmed: 23432159
Infect Dis (Lond). 2016 Apr;48(4):287-292
pubmed: 26635179
J Antimicrob Chemother. 2017 Feb;72(2):616-618
pubmed: 27733516
Int J Antimicrob Agents. 2010 Mar;35(3):282-7
pubmed: 20036520
Int J Antimicrob Agents. 2015 May;45(5):477-84
pubmed: 25769787
Lancet. 2002 Mar 2;359(9308):803
pubmed: 11888633
Acta Derm Venereol. 2015 May;95(5):532-5
pubmed: 25367860
Eur J Clin Microbiol Infect Dis. 2009 Aug;28(8):909-12
pubmed: 19271250
J Pak Med Assoc. 2009 May;59(5):266-9
pubmed: 19438125
Microb Pathog. 2016 Aug;97:89-93
pubmed: 27265678
Diagn Microbiol Infect Dis. 2016 Sep;86(1):66-9
pubmed: 27352729
Med Princ Pract. 2013;22:535-9
pubmed: 23635861
Med Princ Pract. 2008;17(1):71-5
pubmed: 18059105
J Antimicrob Chemother. 2012 Apr;67(4):837-40
pubmed: 22240400
J Hosp Infect. 2004 Jul;57(3):253-7
pubmed: 15236856
Infect Drug Resist. 2018 Oct 24;11:1945-1957
pubmed: 30498366
New Microbes New Infect. 2014 Jul;2(4):100-5
pubmed: 25356354
Scand J Infect Dis. 2007;39(11-12):1059-62
pubmed: 17852934
Clin Infect Dis. 2011 Jun;52 Suppl 7:S487-92
pubmed: 21546625
Diagn Microbiol Infect Dis. 2013 Sep;77(1):20-4
pubmed: 18394845
Exp Dermatol. 2008 Nov;17(11):953-7
pubmed: 18557929
Ann Clin Microbiol Antimicrob. 2010 Nov 04;9:31
pubmed: 21050425
J Antimicrob Chemother. 2010 Jul;65(7):1353-8
pubmed: 20430787
Acta Derm Venereol. 2010;90(1):52-7
pubmed: 20107726
Mol Microbiol. 2006 Jan;59(2):664-76
pubmed: 16390458
Clin Microbiol Infect. 2003 Aug;9(8):886-92
pubmed: 14616715
Med J Malaysia. 2011 Aug;66(3):276
pubmed: 22111461
Pediatr Allergy Immunol. 2004 Oct;15(5):474-7
pubmed: 15482526
Br J Dermatol. 2003 May;148(5):1018-20
pubmed: 12786835
J Microbiol Immunol Infect. 2013 Jun;46(3):224-33
pubmed: 23523045
Clin Infect Dis. 2008 Jun 1;46 Suppl 5:S350-9
pubmed: 18462090
Antimicrob Agents Chemother. 2003 Jan;47(1):418-20
pubmed: 12499229
Clin Microbiol Infect. 2004 Oct;10(10):890-4
pubmed: 15373882
Ann Clin Microbiol Antimicrob. 2014 Sep 16;13:44
pubmed: 25223381
Int J Antimicrob Agents. 2016 Feb;47(2):155-7
pubmed: 26774158
Ann Dermatol Venereol. 2003 Aug-Sep;130(8-9 Pt 1):723-8
pubmed: 14576601
Clin Infect Dis. 2011 Jun;52 Suppl 7:S493-503
pubmed: 21546626
J Clin Diagn Res. 2016 Sep;10(9):DC32-DC36
pubmed: 27790436
J Clin Microbiol. 2007 May;45(5):1505-10
pubmed: 17344365
Pathol Biol (Paris). 2004 Oct;52(8):493-6
pubmed: 15465271
J Antimicrob Chemother. 2014 Nov;69(11):2913-9
pubmed: 24990868
Eur J Clin Microbiol Infect Dis. 2019 Nov;38(11):2037-2044
pubmed: 31332610
Diagn Microbiol Infect Dis. 2008 Jun;61(2):143-9
pubmed: 18280081
Med Mal Infect. 2004 May;34(5):210-5
pubmed: 16235597
J Cutan Med Surg. 2006 Nov-Dec;10(6):277-80
pubmed: 17241597
J Antimicrob Chemother. 2005 Dec;56(6):1103-6
pubmed: 16223937
Int J Antimicrob Agents. 1999 Aug;12 Suppl 2:S23-34
pubmed: 10528784
Commun Dis Intell Q Rep. 2006;30(4):462-6
pubmed: 17330389
PLoS One. 2013 Nov 26;8(11):e82472
pubmed: 24303083
Br J Dermatol. 1998 Dec;139 Suppl 53:37-40
pubmed: 9990411
Clin Exp Dermatol. 2005 Jan;30(1):10-3
pubmed: 15663492
J Chemother. 2004 Jun;16(3):310-1
pubmed: 15330332
FEMS Microbiol Rev. 2017 May 1;41(3):430-449
pubmed: 28419231
Pathology. 2001 May;33(2):206-10
pubmed: 11358055
J Infect Dev Ctries. 2018 May 31;12(5):321-325
pubmed: 31865293
Br J Ophthalmol. 2001 Jul;85(7):842-7
pubmed: 11423460
ERJ Open Res. 2016 Mar 15;2(1):
pubmed: 27730175
FEMS Immunol Med Microbiol. 2012 Mar;64(2):212-8
pubmed: 22066960
J Antimicrob Chemother. 2011 Jun;66(6):1360-4
pubmed: 21393202
Clin Exp Dermatol. 2009 Mar;34(2):136-9
pubmed: 18828847
Isr Med Assoc J. 2005 Mar;7(3):148-50
pubmed: 15792257
Med J Malaysia. 2005 Oct;60(4):411-5
pubmed: 16570701
Eur J Microbiol Immunol (Bp). 2019 Oct 16;9(4):124-130
pubmed: 31934364
Acta Otolaryngol. 2002 Dec;122(8):827-30
pubmed: 12542200
J Med Microbiol. 2002 Dec;51(12):1113-1116
pubmed: 12466411
PLoS One. 2016 Sep 15;11(9):e0162744
pubmed: 27631623
Antimicrob Agents Chemother. 2010 Dec;54(12):4985-91
pubmed: 20855746
Commun Dis Intell Q Rep. 2013 Sep 30;37(3):E210-8
pubmed: 24890956
Microb Drug Resist. 2004 Summer;10(2):160-8
pubmed: 15256032
J Pak Med Assoc. 2007 Jan;57(1):2-4
pubmed: 17319409
Future Microbiol. 2014;9(6):737-45
pubmed: 25046521
Ann Dermatol. 2016 Aug;28(4):470-8
pubmed: 27489430
Br J Dermatol. 2006 Feb;154(2):239-43
pubmed: 16433791
Med Dosw Mikrobiol. 2002;54(4):285-92
pubmed: 12650051
Eur J Clin Microbiol Infect Dis. 2010 Feb;29(2):163-70
pubmed: 19911206
BMC Infect Dis. 2006 Nov 25;6:168
pubmed: 17125522
J Infect. 2004 Aug;49(2):109-14
pubmed: 15236917
Am J Infect Control. 2014 Feb;42(2):160-3
pubmed: 24360641
PLoS One. 2013;8(2):e56466
pubmed: 23424663
J Clin Microbiol. 2014 Apr;52(4):1182-91
pubmed: 24501024
Expert Rev Anti Infect Ther. 2009 Apr;7(3):269-79
pubmed: 19344241
Microb Drug Resist. 2020 Jun;26(6):661-669
pubmed: 31910349
Int J Antimicrob Agents. 2019 Mar;53(3):261-267
pubmed: 30412736
Burns. 2012 Aug;38(5):738-42
pubmed: 22360963
Antimicrob Agents Chemother. 2006 Jan;50(1):55-61
pubmed: 16377667
Pathology. 2008 Jan;40(1):64-71
pubmed: 18038318
Medicina (Kaunas). 2006;42(4):332-9
pubmed: 16687905
Antimicrob Agents Chemother. 2012 Oct;56(10):5340-55
pubmed: 22869569
Coll Antropol. ;40(2):133-7
pubmed: 29139628
Antimicrob Agents Chemother. 2011 Mar;55(3):1173-6
pubmed: 21149625
J Pak Med Assoc. 2017 Nov;67(11):1743-1746
pubmed: 29171572
J Glob Antimicrob Resist. 2017 Sep;10:101-105
pubmed: 28729209
Mikrobiyol Bul. 2002 Apr;36(2):141-5
pubmed: 12652865
Pak J Pharm Sci. 2018 Mar;31(2):429-437
pubmed: 29618431
Lancet. 2002 Sep 7;360(9335):806
pubmed: 12241858
J Clin Microbiol. 2008 Jan;46(1):62-8
pubmed: 17989197
J Antimicrob Chemother. 2009 Feb;63(2):420-1; author reply 421
pubmed: 18978362
Crit Rev Anal Chem. 2016 Jul 3;46(4):352-60
pubmed: 26337404
Infect Dis (Lond). 2019 Nov - Dec;51(11-12):878-879
pubmed: 31448975
Postepy Dermatol Alergol. 2017 Dec;34(6):553-560
pubmed: 29422820
PLoS One. 2018 Apr 18;13(4):e0195933
pubmed: 29668723
J Glob Antimicrob Resist. 2017 Sep;10:223-227
pubmed: 28735049
BMC Microbiol. 2011 May 12;11:98
pubmed: 21569422
Microb Pathog. 2016 Apr;93:8-12
pubmed: 26796298
Clin Microbiol Infect. 2003 Feb;9(2):153-6
pubmed: 12588338
Afr Health Sci. 2014 Dec;14(4):802-9
pubmed: 25834486
Ann Clin Microbiol Antimicrob. 2007 May 23;6:5
pubmed: 17521424
Tidsskr Nor Laegeforen. 2003 Sep 25;123(18):2557-60
pubmed: 14714041
Infect Drug Resist. 2018 Aug 14;11:1175-1182
pubmed: 30147345
Clin Infect Dis. 2011 Jun;52 Suppl 7:S477-86
pubmed: 21546624